menu
    • menu
    [{"orgOrder":0,"company":"Avance Clinical","sponsor":"Atossa Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"AT-301","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Avance Clinical \/ Atossa Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Avance Clinical \/ Atossa Therapeutics"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Odyssey Health","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"PRV-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"EB-373","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"5","companyTruncated":"Avance Clinical \/ Avance Clinical"},{"orgOrder":0,"company":"Avance Clinical","sponsor":"Oragenics","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2024","type":"Partnership","leadProduct":"ONP-002","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Avance Clinical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Avance Clinical \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Avance Clinical \/ Avance Clinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Avance Clinical

    Menu

    Avance Clinical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Avance Clinical

                            Australia arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Avance Clinical

                            Australia arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONP-002

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I

                            Recipient : Oragenics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia

                            Details : The partnership aims to evaluate Oragenics' lead drug candidate, ONP-002, a NCE delivered through a unique intranasal device, for mild Traumatic Brain Injury.

                            Brand Name : PRV-002

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 07, 2024

                            Lead Product(s) : ONP-002

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I

                            Recipient : Oragenics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Avance Clinical

                            Australia arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Avance Clinical

                            Australia arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EB-373

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Recipient : Enveric Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373

                            Details : Under the agreement, Avance Clinical will manage the Phase 1 clinical trial of EB-373 in coordination with Enveric. EB-373 is designed as a next-generation proprietary psilocin prodrug and developed leveraging its Psybrary™ drug discovery platform to t...

                            Brand Name : EB-373

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 23, 2023

                            Lead Product(s) : EB-373

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Recipient : Enveric Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Avance Clinical

                            Australia arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Avance Clinical

                            Australia arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRV-002

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I

                            Recipient : Odyssey Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug

                            Details : No severe adverse events were noted as PRV-002 was well-tolerated for all cohorts. No delays were instituted between cohorts. Vital signs, EKG readings, sleep patterns and breathing function were all normal through the entirety of the study.

                            Brand Name : PRV-002

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 28, 2022

                            Lead Product(s) : PRV-002

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I

                            Recipient : Odyssey Health

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Avance Clinical

                            Australia arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Avance Clinical

                            Australia arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Atossa Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Avance Clinical Contracted for Atossa Therapeutics AT-301 Nasal Spray Clinical Study

                            Details : The study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups.

                            Brand Name : AT-301

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 22, 2020

                            Lead Product(s) : AT-301

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Atossa Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth